Novartis reports positive Phase III trial results of Arzerra in patients with relapsed CLL
The safety profile observed in this trial is consistent with other trials of Arzerra and no new safety signals were observed. "Patients eventually stop responding to current CLL
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.